Drug intelligence / Profile preview

recombinant human interferon chimera

Development stage: Preclinical
Lead developer: Heligenics
Modality: Recombinant Proteins and Enzymes

Overview

Recombinant human interferon chimera is a protein-based therapeutic candidate being developed by Heligenics. It is designed as a dual gene agonist targeting the interferon-alpha2 receptor (IFNAR). The drug is engineered as a chimeric protein to optimize interferon signaling pathways, potentially offering improved efficacy and safety profiles compared to standard interferon-alpha treatments. It is currently in the lead validation (preclinical) stage for the treatment of acute myeloid leukemia (AML), squamous cell carcinoma, polycythemia vera, and various viral infections.

Other names: Recombinant Human Interferon Chimeras

Targets

IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)

Beyond the preview

Go deeper on recombinant human interferon chimera.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human interferon chimera.

Explore the full profile